Gilead Sciences Now Covered by Argus (GILD)

Share on StockTwits

Argus assumed coverage on shares of Gilead Sciences (NASDAQ:GILD) in a report issued on Monday. The firm issued a buy rating and a $110.00 target price on the stock.

In other Gilead Sciences news, Director Richard James Whitley unloaded 5,000 shares of the stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $91.00, for a total transaction of $455,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Gilead Sciences (NASDAQ:GILD) traded up 0.18% on Monday, hitting $93.089. The stock had a trading volume of 5,512,570 shares. Gilead Sciences has a 52 week low of $55.96 and a 52 week high of $94.34. The stock has a 50-day moving average of $88.49 and a 200-day moving average of $80.80. The company has a market cap of $140.7 billion and a price-to-earnings ratio of 21.05. Gilead Sciences also saw a significant increase in short interest during the month of July. As of July 31st, there was short interest totalling 98,473,543 shares, an increase of 3.1% from the July 15th total of 95,485,621 shares. Based on an average daily trading volume, of 14,643,274 shares, the days-to-cover ratio is presently 6.7 days. Approximately 6.5% of the company’s stock are short sold.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Wednesday, July 23rd. The company reported $2.36 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.73 by $0.63. The company had revenue of $6.53 billion for the quarter, compared to the consensus estimate of $5.68 billion. During the same quarter last year, the company posted $0.50 earnings per share. Gilead Sciences’s revenue was up 136.1% compared to the same quarter last year. On average, analysts predict that Gilead Sciences will post $8.02 earnings per share for the current fiscal year.

GILD has been the subject of a number of other recent research reports. Analysts at Zacks upgraded shares of Gilead Sciences from a neutral rating to an outperform rating in a research note on Thursday, August 7th. They now have a $111.00 price target on the stock. Finally, analysts at Maxim Group raised their price target on shares of Gilead Sciences from $112.00 to $127.00 in a research note on Monday, July 28th. They now have a buy rating on the stock. One analyst has rated the stock with a hold rating and nineteen have given a buy rating to the stock. Gilead Sciences presently has an average rating of Buy and an average price target of $103.32.

Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.

Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.

Latest News

Apple Frenzy as Stores Start Selling iPhone 6
Apple Frenzy as Stores Start Selling iPhone 6
GlaxoSmithKline Fined Close to $500 Million by China
GlaxoSmithKline Fined Close to $500 Million by China
Japan Sees Another Trade Deficit
Japan Sees Another Trade Deficit
Sony Says Losses Will Reach $2 Billion
Sony Says Losses Will Reach $2 Billion
UK Inflation Drops During August
UK Inflation Drops During August
Lufthansa and Air France Hit By Pilot Strikes
Lufthansa and Air France Hit By Pilot Strikes


Leave a Reply

 
 
© 2006-2014 Ticker Report. Google+.